| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.3 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.3 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | 0.04 | 0.3 |
| mRNA | navitoclax:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | Bleomycin | GDSC1000 | pan-cancer | AAC | -0.039 | 0.3 |